Pain in axial spondyloarthritis: role of the JAK/STAT pathway.

"Conflict of interest LN, FM, and BP are employed by AbbVie and may own AbbVie stocks/options. CS has received consulting/speakers’ fees from AbbVie, Amgen, Alfa-Sigma, Biogen, Eli-Lilly, EUSA Pharma-Recordati, Galapagos, Janssen, Novartis, Pfizer, Recordati and SOBI and Research support from AbbVie, Amgen, Janssen, Novartis and Pfizer. MC has received consulting/speakers’ fees from Abbvie, Lilly, Novartis, UCB, Amgen, Janssen. KV has received consultancy and speakers fees, and research grants from Abbvie, Amgen, Celgene, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, and UCB. Research funding to the Chronic arthritis research group: FWRO, IMI, Celgene partner program, UZ Leuven Funding KOOR. FC has received consulting fees from Abbvie, Lilly, Novartis, UCB, Amgen, Janssen, UCB, Lilly, Pfizer, Galapagos, GSK, MSD, Amgen, grant/research support from AbbVie, Novartis and Pfizer. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. The authors declare that this study received funding from AbbVie S.r.l. The funder had the following involvement in the study: writing, reviewing, and approving the publication."

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Medical writing support was provided by Colin Gerard Egan, PhD (CE Medical Writing, SRLS, Pisa, Italy)."